# FDA Hesitant to Approve More CBD Based Products > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/fda-warning-on-cbd-products/ > **Published:** 2020-09-01T14:00:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:17:26-04:00 > **Clinical Summary:** FDA warning on CBD products highlights safety concerns and misinformation risks in the growing CBD market. --- ### FDA Warns of Potential Harm From CBD Products In Summary The spread of misinformation is one of the scariest things in the 21st century. As more and more people become exposed to information on the internet, it is easy for people to write or post information or data that is misleading. Keeping this in mind, the FDA has voiced its warning of skewed data relating to canabindoil products. This is due to the limited information they have on the effects [cannabis products](https://cedclinic.com/texas-hemp-smokeable-ban-lawsuit/) have on the body. CBD differentiates from THC because it treats pain, however; it does not produce a “high” effect like tetrahydrocannabinol. The FDA is not only worried about [CBD products](https://cedclinic.com/texas-hemp-regulatory-lawsuit-challenges-state-rules/) themselves. The agency is also worried about the companies and locations that are producing these products. It voices concern about potential unsafe manufacturing locations where the products are packaged to be mass produced. In addition, the FDA is wary of companies and organizations not being honest about the products that are being marketed to the public. As of 2020, there has only been one drug predominantly containing CBD for treating epilepsy and will use this product as a reference when approving other prescription drugs in the future. [LEARN MORE](https://www.wsj.com/articles/fda-warns-of-potential-harm-from-cbd-products-11574881127?mod=searchresults&page=2&pos=11) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoids vs. Opioids: Exploration and Evolution of Pain Management](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) Explore the evolving role of cannabinoids compared to opioids in [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/), highlighting safety and efficacy considerations. [Read More](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) [The Endocannabinoid System and NSAID Derivative Safety](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) Learn how the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) enhances analgesia and [gastrointestinal safety](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) in new NSAID derivatives. [Discover More](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) [Texas Hemp Rules Set to Take Effect March 31](https://cedclinic.com/texas-hemp-rules-impact-smoke-shops-march-31/) Understand the impact of new Texas hemp regulations on local businesses and the CBD market. [Learn More](https://cedclinic.com/texas-hemp-rules-impact-smoke-shops-march-31/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=FDA%20Hesitant%20to%20Approve%20More%20CBD%20Based%20Products&url=https%3A%2F%2Fcedclinic.com%2Ffda-warning-on-cbd-products%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Ffda-warning-on-cbd-products%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=FDA%20Hesitant%20to%20Approve%20More%20CBD%20Based%20Products%20https%3A%2F%2Fcedclinic.com%2Ffda-warning-on-cbd-products%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).